Zuellig Pharma Corporation, through its commercialization arm ZP Therapeutics, said pharmaceutical firms are expected to heavily invest in their market access capabilities to accelerate vaccine access in the Philippines.
Jeff Folland, Philippines general manager of ZP Therapeutics Pharmaceutical of Zuellig Pharma, noted that companies experience increasing barriers to market access for innovative medicines as the pandemic continues to impact global demand and supply.
Despite these economic tensions, healthcare companies continue to address the pandemic by enabling immediate access to future-ready vaccines.
“Effective market access is a critical component in helping patients trust their respective healthcare systems,” said Folland. “This means pharmaceutical companies should heavily invest in their market access capabilities to ensure safe, effective, and efficient deployment of medical products,” he added.
Folland emphasized that ZP Therapeutics’ role in containing the pandemic illustrates this trend. “As the local partner of biopharmaceutical companies like Moderna TX Inc., ZP Therapeutics is integral in securing regulatory clearances for the Spikevax COVID-19 Vaccine Moderna,” Folland added.
Now, he said, the Philippines has more than 33 million doses of the Spikevax COVID-19 Vaccine Moderna. They are also looking forward to helping the national government procure the next generation of future-ready mRNA boosters once approved by local authorities.
The Philippine Food and Drug Administration (FDA) has recently approved the amended EUA filed by ZP Therapeutics for the Spikevax COVID-19 Moderna for children aged 6-11 years old.
Currently, the Vaccine Expert Panel is studying the bivalent vaccine from Moderna which can produce elevated level of neutralizing antibodies against both Delta and Omicron variants.
Beyond regulatory expertise, ZP Therapeutics relies on scientific market research and commercial expertise to introduce new healthcare innovations to the local market.
“The pandemic taught us the importance of combining commercial expertise and marketing capabilities to facilitate access for COVID-19 vaccines and other relevant treatments to support our healthcare system,” Folland said. He added that addressing need and attaining stakeholder confidence for the brand are crucial to ensure the country’s post-pandemic recovery.
Asia’s leading commercialization partner in the healthcare industry said that it looks forward to continuing helping both public and private sector procure and deliver additional mRNA vaccines for both primary and booster vaccination.
“Our capabilities also ensure that we can effectively manage medical products through all stages of the product life cycle, from procurement to delivery. ZP Therapeutics will do its part in helping our partners have access to future-ready mRNA vaccines with our innovative packaging and vaccine management solutions,” Folland ended.
ZP Therapeutics is the leading healthcare sales, marketing, and commercialization partner in Asia with offices in 13 countries and over 2,500 associates.